Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with
increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

Background COVID-19 infection is associated with D-dimer elevations, high rates of
thrombus formation, and poor clinical outcomes. We sought to determine if empiric …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …

Abstract Background Coronavirus disease 2019 (COVID-19) is associated with a
hypercoagulable state. Limited data exist informing the relationship between anticoagulation …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …